Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Non-alcoholic steatohepatitis-induced fibrosis: Toll-like receptors, reactive oxygen species and Jun N-terminal kinase.

Brenner DA, Seki E, Taura K, Kisseleva T, Deminicis S, Iwaisako K, Inokuchi S, Schnabl B, Oesterreicher CH, Paik YH, Miura K, Kodama Y.

Hepatol Res. 2011 Jul;41(7):683-6. doi: 10.1111/j.1872-034X.2011.00814.x.

2.

NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications.

Farrell GC, van Rooyen D, Gan L, Chitturi S.

Gut Liver. 2012 Apr;6(2):149-71. doi: 10.5009/gnl.2012.6.2.149.

3.

Decoding cell death signals in liver inflammation.

Brenner C, Galluzzi L, Kepp O, Kroemer G.

J Hepatol. 2013 Sep;59(3):583-94. doi: 10.1016/j.jhep.2013.03.033. Review.

4.

Impact of dietary fat on the development of non-alcoholic fatty liver disease in Ldlr-/- mice.

Jump DB, Depner CM, Tripathy S, Lytle KA.

Proc Nutr Soc. 2016 Feb;75(1):1-9.

5.

Role of serum toll-like receptors 2 and 4 in non-alcoholic steatohepatitis and liver fibrosis.

Cengiz M, Ozenirler S, Elbeg S.

J Gastroenterol Hepatol. 2015 Jul;30(7):1190-6. doi: 10.1111/jgh.12924.

PMID:
25684563
6.
7.

Mitochondrial gene polymorphisms alter hepatic cellular energy metabolism and aggravate diet-induced non-alcoholic steatohepatitis.

Schröder T, Kucharczyk D, Bär F, Pagel R, Derer S, Jendrek ST, Sünderhauf A, Brethack AK, Hirose M, Möller S, Künstner A, Bischof J, Weyers I, Heeren J, Koczan D, Schmid SM, Divanovic S, Giles DA, Adamski J, Fellermann K, Lehnert H, Köhl J, Ibrahim S, Sina C.

Mol Metab. 2016 Feb 2;5(4):283-95. doi: 10.1016/j.molmet.2016.01.010.

8.

The indole derivative NecroX-7 improves nonalcoholic steatohepatitis in ob/ob mice through suppression of mitochondrial ROS/RNS and inflammation.

Chung HK, Kim YK, Park JH, Ryu MJ, Chang JY, Hwang JH, Lee CH, Kim SH, Kim HJ, Kweon GR, Kim KS, Shong M.

Liver Int. 2015 Apr;35(4):1341-53. doi: 10.1111/liv.12741.

PMID:
25443620
9.

Adenosine A(2a) receptor stimulation prevents hepatocyte lipotoxicity and non-alcoholic steatohepatitis (NASH) in rats.

Imarisio C, Alchera E, Sutti S, Valente G, Boccafoschi F, Albano E, Carini R.

Clin Sci (Lond). 2012 Sep;123(5):323-32. doi: 10.1042/CS20110504.

PMID:
22439844
10.

The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis.

Griffett K, Welch RD, Flaveny CA, Kolar GR, Neuschwander-Tetri BA, Burris TP.

Mol Metab. 2015 Feb 9;4(4):353-7. doi: 10.1016/j.molmet.2015.01.009.

11.

Pathophysiological mechanisms involved in non-alcoholic steatohepatitis and novel potential therapeutic targets.

Higuera-de la Tijera F, Servín-Caamaño AI.

World J Hepatol. 2015 Jun 8;7(10):1297-301. doi: 10.4254/wjh.v7.i10.1297.

12.

The Ethanol Extract from Lonicera japonica Thunb. Regresses Nonalcoholic Steatohepatitis in a Methionine- and Choline-Deficient Diet-Fed Animal Model.

Tzeng TF, Tzeng YC, Cheng YJ, Liou SS, Liu IM.

Nutrients. 2015 Oct 21;7(10):8670-84. doi: 10.3390/nu7105423.

13.

The role of immune cells in metabolism-related liver inflammation and development of non-alcoholic steatohepatitis (NASH).

Nati M, Haddad D, Birkenfeld AL, Koch CA, Chavakis T, Chatzigeorgiou A.

Rev Endocr Metab Disord. 2016 Mar;17(1):29-39. doi: 10.1007/s11154-016-9339-2. Review.

PMID:
26847547
14.

Hepatocyte Nicotinamide Adenine Dinucleotide Phosphate Reduced Oxidase 4 Regulates Stress Signaling, Fibrosis, and Insulin Sensitivity During Development of Steatohepatitis in Mice.

Bettaieb A, Jiang JX, Sasaki Y, Chao TI, Kiss Z, Chen X, Tian J, Katsuyama M, Yabe-Nishimura C, Xi Y, Szyndralewiez C, Schröder K, Shah A, Brandes RP, Haj FG, Török NJ.

Gastroenterology. 2015 Aug;149(2):468-80.e10. doi: 10.1053/j.gastro.2015.04.009.

15.

Non-alcoholic steatohepatitis in children.

Nanda K.

Pediatr Transplant. 2004 Dec;8(6):613-8. Review.

PMID:
15598336
16.

Are oxidative stress mechanisms the common denominator in the progression from hepatic steatosis towards non-alcoholic steatohepatitis (NASH)?

Tariq Z, Green CJ, Hodson L.

Liver Int. 2014 Aug;34(7):e180-90. doi: 10.1111/liv.12523. Review.

PMID:
24621397
17.

Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.

Liew PL, Lee WJ, Lee YC, Wang HH, Wang W, Lin YC.

Obes Surg. 2006 Dec;16(12):1584-93.

PMID:
17217634
18.

Elevated free cholesterol in a p62 overexpression model of non-alcoholic steatohepatitis.

Simon Y, Kessler SM, Gemperlein K, Bohle RM, Müller R, Haybaeck J, Kiemer AK.

World J Gastroenterol. 2014 Dec 21;20(47):17839-50. doi: 10.3748/wjg.v20.i47.17839.

19.

Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis.

Schierwagen R, Maybüchen L, Zimmer S, Hittatiya K, Bäck C, Klein S, Uschner FE, Reul W, Boor P, Nickenig G, Strassburg CP, Trautwein C, Plat J, Lütjohann D, Sauerbruch T, Tacke F, Trebicka J.

Sci Rep. 2015 Aug 11;5:12931. doi: 10.1038/srep12931.

20.

Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis.

Pizarro M, Solís N, Quintero P, Barrera F, Cabrera D, Rojas-de Santiago P, Arab JP, Padilla O, Roa JC, Moshage H, Wree A, Inzaugarat E, Feldstein AE, Fardella CE, Baudrand R, Riquelme A, Arrese M.

Liver Int. 2015 Sep;35(9):2129-38. doi: 10.1111/liv.12794. Erratum in: Liver Int. 2016 Feb;36(2):314.

Items per page

Supplemental Content

Support Center